Chemung Financial (NASDAQ:CHMG), the parent company of Chemung Canal Trust Company, delivered a historic performance for the first quarter of 2026, reporting record net income of $9.2 million, or $1.91 per share.
Medicus Pharma (NASDAQ:MDCX), a clinical-stage biopharmaceutical company, announced today that it has submitted an application for Orphan Drug Designation (ODD) to the U.S. Food and Drug Administration (FDA) for its flagship candidate, SkinJect (D-MNA).
Truist Financial (NYSE:TFC) reported first-quarter 2026 net income available to common shareholders of $1.4 billion, or $1.09 per diluted share.
Immuron (NASDAQ:IMRN), an Australian-based biopharmaceutical company focused on oral immunotherapy, reported unaudited sales results for the third quarter ended March 31, 2026.
HIVE Digital Technologies is seeking to raise $75 million through exchangeable senior notes to fund data centres and artificial intelligence infrastructure.
Tivan (ASX:TVN) announced an advancement in the commercialisation of its Speewah Fluorite Project.
Lithium Plus Minerals (ASX:LPM) secured $2.2 million through an equity placement to fast-track its flagship Northern Territory operations.
American Uranium (ASX:AMU) announced a substantial expansion of its flagship Lo Herma ISR Uranium Project.
Rhea Finance, a major DeFi hub on the NEAR Protocol, has suffered a $7.6 million exploit involving oracle manipulation and fake token contracts.
5E Advanced Materials (ASX:5EA) announced its decision to voluntarily delist from the Australian Securities Exchange.
